Niraparib is used to treat ovarian cancer, fallopian tube cancer, or a type of cancer of the abdomen (primary peritoneal cancer). It works by slowing the growth of cancer cells. Niraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Niraparib capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Lynparza (olaparib) tablets cost price in India.
The order for Niraparib capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Niraparib capsules, for oral use Initial U.S. Approval: 2017
Generic Name: niraparib
Capsules: 100 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Niraparib capsules on prescription and Import License in Patient's Name only.
For overseas patients, Niraparib capsules can be made available in Send your enquiry to find Niraparib capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For ZEJULA (niraparib) capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
GSK gets FDA nod for wider use of ovarian cancer drug Zejula For More Details
The AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancerReadMore